Rigvir group finalised an ERAF funded project - GLP Toxicity Study of Rigvir

13 October 2020

Rigvir group company Latima Ltd. has successfully finalised
an ERAF funded project – GLP Toxicity Study of RIGVIR.
The total duration of the project was 12 months.
The total cost was 513471.78 EUR, of which 359430.24 EUR were ERAF funding.
The project was performed under contract by Charles River Laboratories UK.
The aims of the project have been reached, and as a result a NOAEL (no adverse effect level) has been determined.
The results of the study will be published.

Contacts for Media Inquiries

Rigvir Group
E-mail: pr@rigvir.com